The emergence of adaptive cardiac devices, especially those that utilise AI, is propelling the wider industry shift towards personalised medicine, according to GlobalData.
“The cardiovascular devices market is undergoing rapid expansion and diversification. AI-enhanced solutions exemplify the industry’s shift toward precision medicine, aligning with regulatory bodies like the FDA prioritising innovative approaches to improve outcomes in cardiovascular disease management,” says GlobalData medical devices analyst Cynthia Stinchcombe.
Adaptive cardiac devices have been identified as a revolutionary approach to heart disease treatment. Unlike traditional pacemakers, adaptive devices work by dynamically adjusting to a patient’s condition. This can be in the form of a coronary implant, such as Elixir Medical’s DynamX bioadaptor, or an AI-driven device that analyses heart activity and adjusts treatment based on fluctuations.
Implantable cardiac monitors developed by Medtronic, for example, use AI to detect atrial fibrillation. Biotronik’s BioMonitor IV with SmartECG uses algorithms to distinguish between premature atrial and ventricular contractions. Adaptive technologies afford a more personalised approach for cardiovascular patients, part of a wider theme that is seeing healthcare move away from a “one size fits all approach”.
Stinchcombe says: “The adoption of cutting-edge technologies in cardiovascular care emphasises the critical role innovation plays in modern healthcare. With these advanced systems, we are moving towards more tailored and effective treatment strategies for heart conditions, improving both quality of life and clinical outcomes.”
A report by GlobalData forecasts the cardiovascular devices market will reach $140bn by 2033, up from $84.8bn in 2023, and growing at a compound annual growth rate (CAGR) of 5.20%.
The role of wearable tech in cardiovascular care is also predicted to help grow the market as patients become empowered to take more control of their health. The British Heart Foundation (BHF) says while these devices cannot provide a diagnosis, they “can be helpful for tracking fitness and noticing if something is out of the ordinary”. In addition, the US Food and Drug Administration (FDA) has approved electrocardiogram (ECG) functions on smartwatches and wearable devices, including products by Apple and Samsung. Combining continuous monitoring from wearable technology with adaptive implants creates a “comprehensive framework for cardiac health management”, according to GlobalData.
Editor's note: This article was updated on 3 January to clarify Elixir Medical's DynamX Bioadaptor is not a stent.
